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Abstract
Introduction
Due to contentious associations between sleep and stroke risk we performed a meta-analysis of
cohort studies and utilized Mendelian randomization (MR).
Material and methods
For the meta-analysis we pooled prospective studies and then reviewed the largest genome-wide
association studies regarding self-reported or accelerometer-derived sleep duration with stroke
[ischemic (IS), cardioembolic (CES), large artery (LAS), small vessel (SVS)]. Inverse variance
weighted method (IVW), weighted median (WM)-based method, MR-Egger and MR-Pleiotropy
RESidual Sum and Outlier (PRESSO) were performed. To determine the impact of single nucleotide
polymorphisms (SNPs) leave-one-out method was applied.
Results
Pooled prospective studies demonstrated shorter (<7h) [n=25 studies, I2 = 71.4, p <0.001; risk ratio
(RR): 1.18, 95%CI: 1.08-1.30, p <0.001] and longer (>8h) [n=16 studies, I2 = 53.6, p <0.001; RR:
1.38, 95%CI: 1.24-1.53, p <0.001] sleep increased stroke risk (compared with 7-8h), but were subject
to high levels of heterogeneity. In MR, self-reported sleep duration had no significant effect on IS
(IVW: beta = -0.031, p = 0.747), CES (IVW: beta = -0.039, p = 0.849), LAS (IVW: beta = -0.246, p =
0.328) and SVS (IVW: beta = -0.102, p = 0.667) risk. This was also observed for short and long
accelerometer-derived sleep (all p >0.126). Estimated associations had no significant heterogeneity
and MR-PRESSO revealed no outliers. There was low likelihood of pleiotropy (all estimations p
>0.539) and associations were not driven by single SNPs.
Conclusions
Meta-analysis revealed shorter and longer sleep increased total stroke risk, but with high
heterogeneity. MR analysis showed no causal associations between sleep duration and stroke risk.
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ABSTRACT: 
Introduction: Due to contentious associations between sleep and stroke risk we performed a meta-
analysis of cohort studies and utilized Mendelian randomization (MR).  
Material and Methods: For the meta-analysis we pooled prospective studies and then reviewed the 
largest genome-wide association studies regarding self-reported or accelerometer-derived sleep 
duration with stroke [ischemic (IS), cardioembolic (CES), large artery (LAS), small vessel (SVS)]. Inverse 
variance weighted method (IVW), weighted median (WM)-based method, MR-Egger and MR-Pleiotropy 
RESidual Sum and Outlier (PRESSO) were performed. To determine the impact of single nucleotide 
polymorphisms (SNPs) leave-one-out method was applied.  
Results: Pooled prospective studies demonstrated shorter (<7h) [n=25 studies, I2 = 71.4, p <0.001; risk 
ratio (RR): 1.18, 95%CI: 1.08-1.30, p <0.001] and longer (>8h) [n=16 studies, I2 = 53.6, p <0.001; RR: 1.38, 
95%CI: 1.24-1.53, p <0.001] sleep increased stroke risk (compared with 7-8h), but were subject to high 
levels of heterogeneity. In MR, self-reported sleep duration had no significant effect on IS (IVW: beta = -
0.031, p = 0.747), CES (IVW: beta = -0.039, p = 0.849), LAS (IVW: beta = -0.246, p = 0.328) and SVS (IVW: 
beta = -0.102, p = 0.667) risk. This was also observed for short and long accelerometer-derived sleep (all 
p >0.126). Estimated associations had no significant heterogeneity and MR-PRESSO revealed no outliers. 
There was low likelihood of pleiotropy (all estimations p >0.539) and associations were not driven by 
single SNPs. 
Conclusions: Meta-analysis revealed shorter and longer sleep increased total stroke risk, but with high 
heterogeneity. MR analysis showed no causal associations between sleep duration and stroke risk. 
 





Stroke is a major cardiovascular (CV) event that can lead to brain tissue damage and functional 
disability, as well as death (1). Due to these detrimental effects of stroke, evaluating stroke risk factors 
can be of high importance to prevent this potentially fatal CV disease (CVD) or determine its outcomes. 
Sleep duration is recognised as a major factor for a healthier lifestyle and improved cardiac 
function (2). In this context, sleeping patterns (i.e. short or long duration) have been closely linked to 
morbidity and mortality (3, 4), as well as with chronic cardiometabolic disease, including obesity, 
hypertension, diabetes, respiratory diseases, coronary heart disease and reduced renal function (CHD) 
(2, 5-9). There are several parameters that can influence sleep duration, such as cultural, social, 
psychological, behavioral, pathophysiological and environmental factors (10, 11).  
Considering the potential harmful effects of unfavourable sleep duration on public health, it is 
clinically important to establish whether causality exists between sleep duration and CVD. Recent 
studies showed that sleep duration may be a risk factor for CVD (12). Both short (<7 h) and long (>8 h) 
sleep duration have been related to a greater risk of myocardial infarction (MI) (12-14). However, the 
National Health and Nutrition Examination Survey (NHANES), the Nurses’ Health Study (NHS) and the 
Monitoring Trends and Determinants on Cardiovascular Disease (MONICA) Augsburg cohort study 
reported inconsistent findings regarding the association between sleep duration and CHD risk (5, 15, 16). 
A prospective study of 461,347 UK Biobank (UKB) individuals found that short and long sleep duration 
had a 20 and 34% higher risk of incident MI compared with sleeping 6 - 9 h, respectively, independent of 
individuals' genetic predisposition to CHD (17).  
With regards to stroke, epidemiological studies showed a significant association between long 
sleep duration and stroke risk (16, 18, 19). In contrast, no significant relationship between sleep 
duration and  stroke risk was observed in another prospective cohort study of 2,282 males (20). Previous 
systematic reviews evaluated the links between sleep duration, CV outcomes and all-cause death (11, 
12), reporting that both short and long duration of sleep were associated with a greater risk of total 
mortality and/or CVD morbidity, including CHD and stroke. However, the high heterogeneity between 
the studies was a limitation, making it difficult to draw safe conclusions or support causal inference.  
Given the controversial evidence on the potential role of sleep duration on CVD outcomes and 
its importance for public health, there is an unmet need to elucidate this link in terms of developing 





studies provide only simple estimates of the associations between sleep duration and disease risk, and 
they are prone to bias. Therefore, Mendelian Randomization (MR) studies can evaluate these 
relationships with the use of a large-scale genetic data [involving single nucleoid polymorphisms (SNPs) 
as proxies for lifetime exposure] to provide a more reliable indication of a causal role of sleep duration 
on stroke risk (21). 
In the present study, a comprehensive systematic review and meta-analysis was conducted to 
examine the associations between sleep duration and the risk of total stroke based on data from 
prospective cohort studies. Second, a MR analysis was performed to assess the associations between 
sleep duration (<7 vs >8 h) and different types of stroke, surpassing the limitations of the 
epidemiological studies (i.e. residual bias, confounding factors and reverse causation) (22).  
 
METHODS  
 [A] Cohort studies 
Literature search and study selection 
The meta-analysis was designed, conducted and reported, according to the Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) guidelines (23) (the MOOSE checklist is provided in 
Supplementary Table 1). The primary exposure of interest was sleep duration and stroke was the 
primary outcome. Prospective cohort studies published up to 31 October 2019 (without language 
restriction) were searched using the PubMed, Embase, and Scopus databases; the query search syntax is 
shown in Supplementary Table 2. When required, further searches were performed regarding the 
reference list of eligible articles, previous reviews or meta-analyses, as well as email correspondence 
with authors for additional data.  
 
Study Selection 
Predefined inclusion criteria (see below) were used to determine prospective cohort studies 
regarding the association between sleep duration and stroke risk. Duplicates were removed and then 
titles and abstracts were screened by two reviewers (MM and NS). To avoid bias, both reviewers were 
blinded to the names, qualifications or the affiliations of the study authors. The overall agreement 
between both reviewers was excellent (Kappa index: 0.91; p <0.001) and a meeting was held to resolve 
any disagreements between reviewers prior to articles being retrieved (a flow chart outlining this 




We included studies if the following criteria were met: (1) the topic of interest was sleep duration; 
(2) the studies were population-based cohort studies which reported stroke risk data; (3) relative risk 
(RR), hazard ratio (HR) or odds ratio (OR) estimates with 95% confidence interval (CI) adjusted for 
multivariable factors were available or could be calculated.  
We excluded studies if the following criteria were met: (1) narrative reviews, reviews, comments, 
opinion papers, methodological reports, editorials, letters, or any other publications lacking primary 
data and/or specific descriptions of the methods which were used; (2) not population-based cohort 
studies; (3) RR, HR or OR estimates with 95%CI were either not available or could not be calculated.  
 
Data extraction and management 
The full text of studies meeting the inclusion criteria were retrieved and eligibility was determined 
via screening by two reviewers (MM and NS). An assessment of study quality was determined using the 
Newcastle-Ottawa Scale (NOS) (Supplementary Table 3) (24). Furthermore, sources of funding 
pertaining to each eligible study was investigated. Following an assessment of methodological quality, 
both reviewers (MM and NS) extracted data using a purpose-designed data extraction form. Using this 
data the most important results from each study were summarized by each reviewer independently. 
Both summaries were then compared, and a third reviewer (MB) to then consulted to resolve any 
differences. Any necessary additional calculations regarding the study data, were performed by the first 
reviewer (MM) and verified by the second reviewer (NS). Specific information which was extracted from 
each eligible study included: author, year and references, study name, proportion male, mean age, 
follow-up time (Years), assessment of sleep duration, main confounders (Table 1). 
 
Data synthesis and statistical analyses 
For those studies which reported results from a variety of multivariable-adjusted models, only the 
model with the most confounding factors was incorporated into the meta-analysis. A random-effect 
model was employed to generate pooled RRs, 95%CI and p values for heterogeneity. RRs comparing the 
highest and lowest categories were combined across studies to determine summary associations. The 
extent of heterogeneity across studies was examined using the I2 test (25-27); an I2 >50% with a two-







To determine potential publication bias Begg’s funnel plot asymmetry was investigated by visual 
inspection and Begg’s rank correlation and Egger’s weighted regression tests were also used (28). To 
adjust for the effects of publication bias the Duval and Tweedie trim method was utilized (28). 
Comprehensive Meta-Analysis (CMA) V3 software (Biostat, NJ) was used to conduct the meta-analysis 
(29). 
 
[B] Mendelian Randomization 
Study design 
For our MR study a two-sample MR study design was used and the largest genome wide association 
studies (GWAS) on sleep duration (objectively and subjectively measured) and interested outcomes 
were used to obtain summary statistics. We then applied methods to estimate the unbiased effect of 
sleep traits on the risk of different types of stroke [i.e. ischemic (IS), cardioembolic (CES), large artery 
(LAS), small vessel (SVS)]. 
 
Genetic instruments for sleep duration 
Procedures pertaining to genotyping, quality control, and imputation which have been used in 
the UKB have been previously described (30). From the largest GWAS, 78 SNPs were identified to be 
associated with sleep duration (self-reported) among individuals of European ancestry (n = 446,118) 
(Supplementary Table 4) (31). We hypothesized that the link between sleep duration and stroke risk 
might be non-linear; therefore, we also used data pertaining to 27 SNPs associated with short sleep (<7 
h; n = 106,192 cases/305,742 controls) and 8 SNPs related to long sleep (>8 h; n = 34,184 cases/305,742 
controls) in the two-sample MR analysis (31). We applied on the GWAS (n = 85,205 participants), 
performed in the UKB for genetic variants known to be robustly associated with accelerometer-driven 
sleep trait data (nocturnal sleep duration), which were compared with causal estimates obtained by the 
genetic variants associated with self-reported sleep duration (Supplementary Table 4). Data on this 
procedure has been previously published (32). We identified proxy SNPs with a minimum linkage 
disequilibrium (LD) r2 = 0.8 if a SNP was unavailable for the outcome GWAS summary statistics. We 
restricted our genetic instrument to independent SNPs not in linkage disequilibrium (p = 0.0001) to 
minimize bias in effect estimates induced by correlation between SNPs. Herein we will refer to a set of 
SNPs which act as a proxy for sleep duration as “genetic instruments.” 
 





We utilized the largest available extensively genotyped dataset, i.e. the METASTROKE, a 
collaboration of the International Stroke Genetics Consortium to determine genetic associations with 
different ischemic stroke types (33). This dataset included GWAS data on 34,217 IS cases and 404,630 
controls of European ancestry from across 15 studies [subtyped into SVS (n = 5,386), LAS (n = 4,373) and 
CES (n = 7,193)] (33). The majority of the IS cases involved brain imaging confirmation. Approximately 
50% of the cases had IS subtype information (2,365 CES, 2,167 LAS and 1,894 SVS cases) based on the 
Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification (34). Additional phenotype 
descriptions and details of individual studies included in the dataset are available elsewhere (33). 
 
MR analysis 
The effect of 5 instruments were combined using the inverse variance weighted (IVW) method 
as implemented using the TwoSampleMR package within the R environment [version 3.4.2 R Core Team 
(2017)]. Heterogeneity was assessed by the Q value for IVW. The potential effects of pleiotropic variants 
were addressed on the final effect estimate by performing a sensitivity analysis, including weighted 
median (WM) and MR-egger tests (35). To identify instruments which might drive the MR results 
sensitivity analysis was conducted using the leave-one-out method. The WM estimate provides correct 
estimates if SNPs accounting for ≥50% of the weight are valid instruments. To weight the variants 
inverse variance was used and to estimate Cis bootstrapping was applied (35). MR-egger analysis can 
define estimates even under the assumption that all SNPs are invalid instruments if the assumption of 
instrument strength independent of direct effect (InSIDE) is satisfied (35). That said, the InSIDE 
assumption is not easy to verify. The p value of the intercept term from the MR-Egger analysis was used 
to assess the average directional pleiotropy across genetic variants (35). Causal estimates in MR-Egger 
are less precise than those obtained by using IVW MR (36). Indeed, due to its lower statistical power the 
analysis using MR-Egger has a lower false-positive but a higher false-negative rate than IVW (37).  
The Q′ heterogeneity statistic (38) and the MR pleiotropy residual sum and outlier (MR-PRESSO) 
test (38) were both used to assess heterogeneity between individual genetic variant estimates. The Q′ 
statistic uses modified 2nd order weights that are derived from a Taylor series expansion and considers 
the uncertainty in both numerator and denominator of the instrumental variable ratio (38). The MR-
PRESSO framework detects and removes effect estimates which are outliers by regressing the variant-
outcome associations on variant-exposure associations. Then a global heterogeneity test was 
implemented which compares the observed distance between residual sums of squares of all variants to 




addition to this, we also applied an MR-Robust Adjusted Profile Score (RAPS) to correct for pleiotropy 
using robust adjusted profile scores. RAPS can also provide an unbiased causal estimate in the presence 
of weak instruments. We considered all results which were causal estimates that agreed in direction and 
magnitude across MR methods, as well as passing nominal significance in the IVW MR analysis and 
which did not, after applying heterogeneity tests, show evidence of bias from horizontal pleiotropy. To 
assess the instrumental variable analysis “exclusion-restriction” assumption, we used Ensembl release 
(http://useast.ensembl.org/index.html), which contains a base of SNP phenotypes. 
 
Ethics 
The present meta-analysis and MR analysis used published or publicly available summary data 
without involvement of participants or original data collection. Ethical approval for each of the studies 
included in these analyses can be found in the original publications (including informed consent from 
each participant). The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki. 
 
RESULTS: 
Meta-analysis and systematic review 
Of 44 eligible full articles, 12 articles with 594,632 participants met the inclusion criteria (Figure 1). 
The included studies were published between 1997 (16) and 2016 (40), from different countries, 
including the United States of America (3 studies) (16, 19, 41), UK (1 study) (42), Japan (2 studies) (20, 
43), Germany (2 studies) (44, 45), Australia (1 study) (46), China (2 studies) (40, 47) and Sweden (1 
study) (48). A total of 3 studies presented sex-specific results, one study involved only men (20) and 2 
studies only women (19, 47). The age of the participants ranged from 44 (20) to 63 years (46) and the 
follow up duration from 2 (41) to 14 years (20, 44). Basic characteristics of the 12 prospective cohort 
studies are shown in Table 1. 
 
Sleep duration and risk of stroke 
Compared with participants sleeping 7 - 8 h per night (reference group), individuals with <7 h sleep 
had a significantly higher risk of stroke (RR: 1.18, 95%CI: 1.08 - 1.30, p <0.001, n = 25 studies, Figure 2), 
but with a high level of heterogeneity (I2 = 71.4, p <0.001). In gender analysis, stroke risk was 
insignificantly increased by 18% in men (RR: 1.18, 95%CI:  0.88 - 1.58, p = 0.263, n = 4 studies, I2 = 43.5, p 




We then pooled the risk of stroke for those with ≤5 h of sleep who had a significantly greater stroke risk 
compared with the reference group (RR: 1.34, 95%CI: 1.17 - 1.53, p <0.001, n = 13 studies, Figure 3) but 
again with a high level of heterogeneity (I2 = 58.4, p <0.001). No association was observed for 
participants sleeping 6 h per night (compared with the reference group) (RR: 1.07, 95%CI: 0.98 - 1.18, p 
= 0.110, n = 12 studies, I2 = 52.6, p = 0.016, Figure 4). Longer sleep duration (i.e. >8 h) was related to an 
increased stroke risk compared with 7 - 8 h sleep (RR: 1.38, 95%CI: 1.24 - 1.53, p <0.001, n = 16 studies, 
I2 = 53.6, p <0.001, Figure 5). In gender analysis, the risk was 22% in men (RR: 1.22, 95%CI:  1.00 - 1.49, p 
= 0.042, n = 3 studies, I2 = 0.0, p = 0.398) and 24% in women (RR: 1.24, 95%CI: 0.91 - 1.67, p = 0.159, n = 
5 studies, I2 = 81.6, p <0.001).  
Compared with the reference group, >9 h of sleep also significantly increased stroke risk (RR: 1.35, 
95%CI:  1.22 - 1.50, p <0.001, n = 13 studies, I2 = 41.5, p = 0.043), whereas 10 h of sleep did not affect 
the risk (RR: 1.40, 95%CI:  0.95 - 2.07, p = 0.082, n = 3 studies, I2 = 75.7, p = 0.016). It should be noted 
that in all the above comparisons, there was a high level of heterogeneity between the studies.  
 
Sensitivity analysis 
 In the leave-one-out sensitivity analyses, the pooled effect estimates remained similar for the effect 
of both shorter and longer (in comparison with the reference group) sleep duration (RR: 1.18, 95%CI: 
1.08 - 1.30, and 1.38, 95%CI: 1.24 - 1.53, respectively). This confirms that the significant difference 
between the studied groups is the overall effect of all included studies. 
 
Publication bias 
 Egger’s linear regression also supported the absence of any publication bias (intercept = 2.33, 95%CI 
= 1.77, -5.22, p = 0.450). Furthermore, Begg’s rank correlation test (Kendall’s Tau with continuity 
correction = 0.412, z = 0.832, p = 0.452) was not indicative for publication bias.  
 
Mendelian Randomization 
The list of all instruments associations for sleep duration (subjectively and objectively assessed) 
is shown in Supplementary Table 4. The results, expressed as beta-coefficient for sleep duration per one 
standard deviation (SD) increase in outcomes (i.e. stroke risk) are presented in Tables 2-5. Self-reported 
sleep duration had no significant effect on the risk of IS (IVW: beta = -0.031, p = 0.747), CES (IVW: beta = 
-0.039, p = 0.849), LAS (IVW: beta = -0.246, p = 0.328) and SVS (IVW: beta = -0.102, p = 0.667) (Table 2). 




p = 0.739; for CES IVW: beta = -0.072, p = 0.713; for LAS IVW: beta = 0.109, p = 0.664 and for SVS IVW: 
beta = 0.367, p = 0.149) (Table 3).  
Short sleep duration had also no significant impact on the risk of different strokes (for IS IVW: 
beta = 0.343, p = 0.335, for CES IVW: beta = -0.384, p = 0.614, for LAS IVW: beta = 1.321, p = 0.156 and 
for SVS IVW: beta = -0.009, p = 0.990) (Table 4). Similar results were found for long sleep duration (for IS 
IVW: beta = -0.219, p = 0.805, for CES IVW: beta = 1.895, p = 0.279, for LAS IVW: beta = 2.126, p = 0.389 
and for SVS IVW: beta = 1.369, p = 0.508) (Table 5).  
None of the IWV estimates showed any heterogeneity (Tables 2-5). The MR-PRESSO analysis 
also did not show any possibility of outlier for all the estimates. Furthermore, the pleiotropy test, with 
very negligible intercept and insignificant p value, also indicated low chance of the pleiotropy for all 
estimations (all p >0.539, Tables 2-5). The results of the MR-RAPS were identical with the IVW estimates 
in almost all cases, highlighting again a low likelihood of pleiotropy. The results of the leave-one-out 
method demonstrated that the observed associations were not driven by single SNPs.  
 
DISCUSSION: 
In the present study, we performed a comprehensive systematic review and meta-analysis of the 
available prospective cohort studies, as well as conducted a MR analysis to evaluate the potential effects 
of sleep duration on the risk of stroke in a causal model. By pooling prospective studies, we showed that 
shorter and longer sleep duration might be considered as a significant risk factor for stroke. However, 
these results were subjected to a high level of heterogeneity, thus minimizing their validity, and 
highlighting the need for further, more reliable, statistical analyses. In this context, the MR analysis 
showed no association between sleep duration and the risk of different types of stroke, with low levels 
of heterogeneity and pleiotropy. 
Sleep duration is generally not regarded as a traditional risk factor for CVD, but previous studies 
reported a negative association between short and long sleep duration with CVD morbidity (48) and CVD 
risk factors (49). Indeed, sleep duration and circadian rhythm disorders, as well as insomnia have been 
related to stroke (49,50) with approximately half of stroke survivors potentially having insomnia (50).  
Growing evidence suggests that short and long sleep duration may be linked to adverse health 
outcomes, including total mortality (3, 4), CVD events (4, 15, 18, 51), diabetes (52) and hypertension (7, 
8). The exact underlying mechanisms of a potential association between sleep duration and CVD have 
not been established yet. In this context, short sleep duration may increase leptin and ghrelin levels 




may contribute to the development of obesity (54). Increased cortisol secretion and changes in growth 
hormone metabolism have also been reported in relation to short sleep duration (55), as well as low-
grade inflammation, which can predispose to CVD (55,56). Furthermore, epidemiological studies have 
shown that short sleep duration may be related to higher levels of hemoglobin A1C (56), total 
cholesterol, triglycerides and blood pressure (57), which are all CVD risk factors. Sleep disorders have 
also been suggested to affect the outcomes of CVD events (58) 
  Depressive symptoms, low socio-economic status, unemployment and low level of physical activity 
have been linked to long sleep duration and may confound the relationship of sleep duration with 
morbidity and mortality (59, 60). In this context, the observed harmful effects of longer sleep were 
confounded by depression or socioeconomic status (61).  
One previous meta-analysis (n = 74 studies; 3,340,684 participants) reported no significant 
differences in stroke events in relation to self-reported sleep duration shorter or longer than 7 h, 
whereas a moderate increase in stroke mortality was observed in those sleeping ≥7 h (2). A study in 
2,282 males healthy aged 35 - 54 years found no significant association between any sleep duration and 
stroke risk during 14 years of follow-up, after adjustment for potential confounders, including traditional 
CVD risk factors and working status (20). In contrast, another systemic review and meta-analysis of 15 
prospective studies (n = 474,684 male and female individuals; follow-up 6.9 - 25 years) reported that 
both short and long sleep duration were significantly related to a greater risk of stroke (12).  
Ikehara et al. performed a study which included 98,643 individuals (41,489 men and 57,145 
women) aged 40 to 79 years and found that long sleep duration (≥10 h) was associated with a 1.5 to 2-
fold increased mortality from total and ischemic stroke compared with 7 h of sleep (18). In a 10-year 
follow up of the NHANES cohort (n = 7844; aged ≥32 years), long (>8 h) sleep duration was related to a 
higher risk of stroke compared with the reference group (6 to 8 h of sleep) (16). In another meta-
analysis of 16 prospective studies, the lowest stroke risk was observed in those sleeping 7 h per night; of 
note, in cases of >7 h sleep, total stroke risk was increased by 13% for every 1 h increase in sleep 
duration (61). Furthermore, the Women's Health Initiative Observational Study reported that long sleep 
duration was significantly associated with ischemic stroke among postmenopausal women (19). In 
motor-impaired, right hemisphere stroke patients, sleep latencies were longer and sleep efficiency was 
worse in comparison to age-and sex-matched controls (62). Furthermore, in a Taiwan administrative 
data study which included 21,438 participants with insomnia and 64,314 age and sex-matched without 





The present findings should be extrapolated with caution since our analysis has some limitations. In 
this context, we were unable to thoroughly evaluate individual-level confounding factors. Although we 
used different methods in our MR analysis, there might be still a chance of horizontal pleiotropy. 
Furthermore, a high level of heterogeneity was observed in the present meta-analysis. Despite this, the 
present analysis has strengths, including the fact that the MR analysis reduced the risk of potential 
reverse causation and genotypes were assumed to be randomly distributed with respect to confounders.  
In conclusion, pooled data from prospective cohort studies showed that sleep duration may 
increase the risk of stroke, but the high level of heterogeneity observed between studies significantly 
minimizes the validity of these findings. Furthermore, the MR analysis reported no associations between 
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Assessment of sleep 
duration 
Main confounders 
Chen, 2008 (1) 
 
Prospective cohort study, 
USA 
0 unclear 7.5 Interview questioning 
 
Age, race, education, family income, 
employment status, depression, smoking, 
exercise, use of hormone therapy, prior 
cardiovascular disease, diabetes mellitus, 
hypertension, high cholesterol level 
requiring pills and body mass index.  
 
Hamazaki,  2011 
(2) 
 
Prospective cohort study,  
Japan 
100 44 14 Self-administered 
questionnaire  
 
Age, type of job, working hours, mental 
workload, body mass index, mean blood 
pressure, HbA1c, total cholesterol, current 
smoking habit, drinking habit, leisure-time 




Helbig, 2015  (3) 
 
Prospective cohort study, 
Germany 
50 48 14 Interview questioning Age, survey, education , physical activity, 
alcohol consumption, current smoking 
activity, body mass index, hypertension, 
diabetes and dyslipidemia  
 
Leng,  2015 (4) 
 
Prospective cohort study, 
UK 
46 62 9.5 Questionnaire 
 
Age, sex, social class, education, marital 
status, smoking, alcohol intake, hypnotic 
drug use, family history of stroke, body 
mass index, physical activity, depression, 
systolic blood pressure, diastolic blood 
pressure, preexisting diabetes, myocardial 
infarction, cholesterol level and 






Magee, 2011 (5) 
 
Prospective cohort study, 
Australia 
47 63 unclear Self-reported 
questionnaire  
 
Age, sex, country of birth, marital status, 
education, employment status, 
remoteness, body mass index, physical 
activity, smoking, alcohol and screen time.  
 
Qureshi, 1997 (6) 
 
Prospective cohort study, 
USA 
36 unclear 10 Participants were 
interviewed  
 
Age, sex, race, education, cigarette 
smoking, systolic blood pressure, serum 






Prospective cohort study, 
USA 
44 61 2 Participants were 
questioned on sleep 
 
Demographics, stroke risk factors, 
psychological symptoms, health behaviors 
and diet quality.  
 
Song, 2016 (8) 
 
Prospective cohort study, 
China 
79 51 7.9 Interviews, death 
certificates, discharge 
summaries and medical 
records  
 
Age, sex, marital status, income, education 
level, smoking status, physical activity, 
family history of stroke, body mass index, 
blood pressure, blood glucose, total 
cholesterol, lipid-lowering drug use, 
hypoglycemic drug use, history of 
myocardial infarction, snoring status, C-
reactive protein and atrial fibrillation.  
 
Tu, 2012 (9) 
 
Prospective cohort study, 
China 
0 60 4 Participants were 
questioned on sleep  
 
Age, education level, occupational status, 
night-shift work, annual income, 
menopausal status, marital status, number 
of live births, physical activity, passive 
smoking tea consumption, energy intake, 
time spend watching TV and vitamin 
supplement use.  
 
Von Ruesten,  
2012 (10) 
 
Prospective cohort study, 
Germany 
39 49 8 Participants were 
interviewed about their 
sleep  
 
Age, sex, sleeping disorders, alcohol intake, 
smoking status, walking cycling sports, 
employment status, education, body mass 
index, waist-to-hip ratio, hypertension, high 





satisfaction with life, satisfaction with 





Prospective cohort study, 
 Japan 
39 55 10.7 Interview for sleep 
duration  
 
Age, systolic blood pressure, total 
cholesterol, body mass index, smoking 





Prospective cohort study, 
Sweden 
35 unclear 13 Questionnaire 
 
Age, sex, education, employment status, 
smoking, alcohol, snoring, work schedule, 
depressive symptoms, self-rated health, 
physical activity, body mass index, 
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Table 2. Results of the Mendelian Randomization analysis on the associations between self-reported sleep duration and different types of stroke. 
Exposures  MR Heterogeneity Pleiotropy 





IS MR Egger     -0.229  0.341 0.504 MR Egger 48.668    0.445 0.0034  0.0057 0.547 
WM -0.019  0.154 0.901 
IVW -0.031  0.098 0.747 IVW 49.040    0.471 
RAPS 0.004  0.103 0.967 
CES MR Egger     0.537  0.725 0.462 MR Egger 58.130    0.150 -0.010  0.012 0.409 
WM 0.163  0.287 0.569 
IVW -0.039  0.208 0.849 IVW 58.967    0.155 
RAPS 0.055 0.216 0.796 
LAS MR Egger     -0.658  0.878 0.457 MR Egger 51.42584    0.341 0.0072  0.014 0.626 
WM -0.131  0.382 0.731 
IVW -0.246  0.251 0.328 IVW 51.68298    0.369 
RAPS -0.249  0.259 0.336 
SVS MR Egger     -0.369  0.832 0.658 MR Egger 53.354  0.275 0.0046  0.013 0.738 
WM -0.175  0.367 0.634 
IVW -0.102  0.238 0.667 IVW 53.479     0.306 
RAPS -0.159  0.258 0.536 
Weighted median: WM, Inverse variance weighted: IVW, SE: standard error, beta:  beta-coefficients, RAPS: MR-Robust Adjusted Profile Score, MR: 











Table 3. Results of the Mendelian Randomization analysis on the associations between accelerometer derived sleep duration and different types of stroke. 
Exposures MR Heterogeneity Pleiotropy 






IS MR Egger     -0.043  0.261 0.874 MR Egger 3.344     0.764 0.0037  0.011 0.759 
WM -0.006  0.132 0.963 
IVW 0.033  0.102 0.739 IVW 3.446  0.840 
RAPS 0.034  0.105 0.746 
CES MR Egger     0.233  0.523 0.671 MR Egger 2.190    0.901 -0.014  0.023 0.550 
WM -0.039  0.256 0.878 
IVW -0.072  0.198 0.713 IVW 2.590   0.920 
RAPS -0.073  0.205 0.720 
LAS MR Egger     -0.351  0.683 0.625 MR Egger 6.404   0.379 0.0223  0.030 0.492 
WM -0.132  0.336 0.693 
IVW 0.109  0.253 0.664 IVW 6.975  0.431 
RAPS 0.056  0.273 0.835 
SVS MR Egger     0.038  0.720 0.959 MR Egger 7.557    0.272 0.0157  0.031 0.639 
WM 0.252  0.320 0.430 
IVW 0.367  0.254 0.149 IVW 7.863    0.344 
RAPS 0.353  0.266 0.185 
Weighted median: WM, Inverse variance weighted: IVW, SE: standard error, beta:  beta-coefficients, RAPS: MR-Robust Adjusted Profile Score, MR: 












Table 4. Results of the Mendelian Randomization analysis on the associations between short sleep duration and different types of stroke. 
Exposures  MR Heterogeneity Pleiotropy 




IS MR Egger     1.123  1.70 0.515 MR Egger 15.057  0.820 -0.0053  0.0114 0.643 
WM 0.261  0.461 0.571 
IVW 0.343  0.356 0.335 IVW 15.278   0.850 
RAPS 0.323  0.373 0.386 
CES MR Egger     2.089  3.732 0.581 MR Egger 26.571    0.185 -0.0169 0.0250 0.505 
WM -1.590  0.986 0.106 
IVW -0.384  0.763 0.614 IVW 27.152    0.205 
RAPS -0.755  0.764 0.322 
LAS MR Egger     2.098  4.559 0.650 MR Egger 24.291   0.2791 -0.0053  0.0307 0.863 
WM 1.583  1.191 0.183 
IVW 1.321  0.932 0.156 IVW 24.327    0.3303 
RAPS 1.437  0.935 0.124 
SVS MR Egger     -0.047  3.901 0.990 MR Egger 21.220   0.445 0.00026  0.0263 0.992 
WM -0.004  1.098 0.996 
IVW -0.009  0.822 0.990 IVW 21.220    0.507 
RAPS -0.136  0.865 0.875 
Weighted median: WM, Inverse variance weighted: IVW, SE: standard error, beta:  beta-coefficients, RAPS: MR-Robust Adjusted Profile Score, MR: 











Table 5. Results the Mendelian Randomization analysis on the associations between long sleep duration and different types of stroke. 
Exposures  MR Heterogeneity Pleiotropy 




IS MR Egger     1.836  2.531 0.495 MR Egger 2.311     0.888 -0.012  0.0139 0.418 
WM -0.132  1.096 0.903 
IVW -0.219  0.891 0.805 IVW 3.064   0.878 
RAPS -0.222  0.929 0.810 
CES MR Egger     -3.836  5.247 0.492 MR Egger 4.742   0.577 0.0328  0.0283 0.290 
WM 2.074  2.229 0.352 
IVW 1.895  1.751 0.279 IVW 6.085  0.529 
RAPS 2.396  1.845 0.194 
LAS MR Egger     16.35  6.517 0.045 MR Egger 3.113     0.794 -0.0823  0.0355 0.059 
WM 3.095  2.898 0.285 
IVW 2.126  2.472 0.389 IVW 8.521     0.288 
RAPS 3.084  2.702 0.253 
SVS MR Egger     5.993  5.924 0.350 MR Egger 3.877     0.693 -0.027  0.0325 0.436 
WM 1.313  2.640 0.619 
IVW 1.369  2.072 0.508 IVW 4.571    0.712 
RAPS 1.394  2.178 0.522 
Weighted median: WM, Inverse variance weighted: IVW, SE: standard error, beta:  beta-coefficients, RAPS: MR-Robust Adjusted Profile Score, MR: 





Supplementary Table 1. MOOSE Reporting Checklist for Authors, Editors, and Reviewers of Meta-analyses of Observational Studies 
 




Description of study outcome(s) 
Type of exposure or intervention used 








Reporting of search strategy should include: Page 
number: 
Qualifications of searchers (eg, librarians and investigators) 
Search strategy, including time period included in the synthesis and keywords Effort 
to include all available studies, including contact with authors Databases and 
registries searched 
Search software used, name and version, including special features used (eg, explosion) Use of 
hand searching (eg, reference lists of obtained articles) 
List of citations located and those excluded, including justification Method of 
addressing articles published in languages other than English Method of 
handling abstracts and unpublished studies 

















Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be 
tested 
Rationale for the selection and coding of data (eg, sound clinical principles or convenience) 
Documentation of how data were classified and coded (eg, multiple raters, blinding, and interrater reliability) 
Assessment of confounding (eg, comparability of cases and controls in studies where appropriate) 
Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictors of study 
results 
Assessment of heterogeneity 
Description of statistical methods (eg, complete description of fixed or random effects models, 
justification of whether the chosen models account for predictors of study results, 










Provision of appropriate tables and graphics Tables and 
Figures 
Reporting of results should include: Page 
number: 
Graphic summarizing individual study estimates and overall estimate Table 
giving descriptive information for each study included 
Results of sensitivity testing (eg, subgroup analysis) 





Reporting of discussion should include: Page 
number: 
Quantitative assessment of bias (eg, publication bias) 
Justification for exclusion (eg, exclusion of non–English-language citations) 




Reporting of conclusions should include: Page 
number: 
Consideration of alternative explanations for observed results 
Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the 
literature review) 
Guidelines for future research 
















































Supplementary Table 2. Full search terms and strategy for papers indexed in PUBMED. 
No Concept Search terms 
1 Stroke cerebrovascular[tiab] OR stroke[tiab] OR TIA[tiab] OR transient 
ischemic*[tiab] OR CVA[tiab] OR cerebral infarction[tiab] OR 
Cerebrovascular accident [Mesh:NoExp]  OR stroke[Mesh:NoExp] 
2 Sleep duration  
sleep duration [tiab] 
 
3 Combination Exposure And 
Outcome 
#1 AND #2 
4 Limit Rats[Mesh:NoExp]) OR Mice[Mesh:NoExp]) OR rat[Title/Abstract]) OR 
rats[Title/Abstract]) OR mouse[Title/Abstract]) OR mice[Title/Abstract]) OR 
vivo[Title/Abstract]) OR vitro[Title/Abstract]) 






NEWCASTLE – OTTAWA QUALITY ASSESSMENT SCALE - COHORT STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can 
be given for Comparability.  
 
Selection  
1) Representativeness of the exposed cohort  
a) truly representative of the average healthy adults in the community   
b) somewhat representative of the average healthy adults in the community  
c) selected group of users e.g. nurses, volunteers, vegetarian 
d) no description of the derivation of the cohort  
2) Selection of the non-exposed cohort  
a) drawn from the same community as the exposed cohort   
b) drawn from a different source  
c) no description of the derivation of the non-exposed cohort  
3) Ascertainment of exposure  
a) secure record (e.g. 7 day food diary)   
b) structured interview/≥ 2 dietary recalls/diet history/ food frequency questionnaire validated for dairy components   
c) written self-report (e.g. <2 dietary recalls/non-validated food frequency questionnaire or not reported whether food frequency questionnaire was 
validated)  
d) no description  
4) Demonstration that outcome of interest was not present at start of study  
a) yes  
b) no  
 
Comparability  
1) Comparability of cohorts on the basis of the design or analysis  
a) study controls for age, sex, smoking, total energy intake, and body mass index  
b) study controls for any additional factor (e.g. physical activity, alcohol intake, family history of diabetes, dietary factors)  
 
Outcome  





a) independent blind assessment (e.g. clinical diagnosis/complete medical information available).  
b) record linkage/medical record or validated self-report  
c) non-validated self-report 
d) no description  
2) Was follow-up long enough for outcomes to occur  
a) yes/ follow up period for outcome of interest is 10 years or over  
b) no  
3) Adequacy of follow-up of cohorts  
a) complete follow-up - all subjects accounted for   
b) subjects lost to follow-up unlikely to introduce bias - small number lost ≤20% follow-up, or description provided of those lost  
c) follow-up rate <80% or no description of those lost  
d) no statement 
 
 
Supplemental Table 3. Quality assessment of selected cohorts studies.  
 
Studies 



















of cohorts on 
the basis of 
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Supplementary Table 4. Summary results of the genetic loci of self-reported or derived by 
accelerometer sleep duration   
 
SNP GX GX SE EA OA EAF 
Self-reported sleep duration   
rs915416 0.019259 0.002495 C G 0.289947 
rs269054 -0.01364 0.002293 T A 0.577924 
rs12567114 -0.01483 0.00254 G A 0.724198 
rs62120041 0.026111 0.004575 T C 0.933902 
rs374153 0.017612 0.003103 C T 0.158085 
rs75539574 -0.03625 0.004065 A C 0.914208 
rs7556815 -0.04072 0.00274 G A 0.780856 
rs12611523 0.012635 0.002276 A G 0.545244 
rs4538155 -0.01298 0.002374 C T 0.352574 
rs10173260 -0.01284 0.002313 T C 0.393765 
rs112230981 0.031528 0.005228 A G 0.94984 
rs17732997 0.012935 0.002288 C G 0.569098 
rs7644809 0.013062 0.002301 T C 0.421606 
rs13088093 -0.01627 0.002402 T G 0.663683 
rs2192528 0.013369 0.002269 A G 0.480065 
rs17427571 0.013826 0.002435 A G 0.684313 
rs35531607 -0.01284 0.002273 T C 0.525917 
rs13109404 0.031204 0.004408 T G 0.928024 
rs365663 0.014629 0.002279 A G 0.545963 
rs56372231 -0.01694 0.0024 C T 0.665907 
rs180769 0.012724 0.002294 T C 0.424698 
rs151014368 -0.01609 0.00282 G A 0.793742 
rs34556183 0.016923 0.002523 A G 0.719606 





rs9382445 0.014536 0.002334 T C 0.62305 
rs2231265 -0.01496 0.002699 A G 0.227711 
rs34731055 -0.01946 0.002948 C T 0.81911 
rs2079070 0.017548 0.002566 C G 0.264613 
rs7806045 0.014792 0.002626 T C 0.754703 
rs330088 -0.01447 0.002277 T C 0.452988 
rs10973207 -0.02043 0.003124 G T 0.842323 
rs1776776 0.019963 0.003411 T C 0.873832 
rs12246842 0.013395 0.002274 A G 0.459815 
rs10761674 0.012333 0.002266 C T 0.477334 
rs11190970 0.015379 0.002823 G A 0.798661 
rs7915425 0.019064 0.00299 T C 0.174682 
rs1517572 -0.01464 0.002295 A C 0.419464 
rs4592416 -0.01468 0.00227 A G 0.535593 
rs174560 -0.01358 0.002437 T C 0.685785 
rs12791153 -0.02355 0.004217 A T 0.918911 
rs1939455 0.020425 0.003561 G T 0.879446 
rs1263056 0.012799 0.002277 A G 0.519099 
rs34354917 0.013746 0.002501 C A 0.710472 
rs11614986 0.016379 0.002951 A G 0.820952 
rs6575005 0.015564 0.002642 T C 0.757854 
rs61985058 -0.01859 0.003229 C T 0.856824 
rs11621908 0.024095 0.004163 C T 0.917141 
rs8038326 0.01592 0.002541 A G 0.72691 
rs3095508 0.015352 0.002304 C A 0.593529 
rs11643715 -0.0139 0.002497 C G 0.709058 
rs9940646 0.016946 0.002291 C G 0.577569 
rs7503199 0.014745 0.002564 C T 0.734267 





rs12607679 0.020139 0.002593 T C 0.737717 
rs10421649 -0.0133 0.002295 T A 0.44303 
rs2072727 0.013243 0.002285 T C 0.43617 
Accelerometer derived sleep duration   
rs2660302 0.041 0.006 A T 0.811 
rs113851554 0.11 0.011 G T 0.943 
rs62158170 0.054 0.006 G A 0.217 
rs17400325 0.066 0.012 T C 0.958 
rs72828540 0.041 0.005 T C 0.752 
rs9369062 0.033 0.005 C A 0.292 
rs2975734 0.027 0.005 C G 0.561 
rs13282541 0.032 0.005 C T 0.739 
rs2880370 0.028 0.005 A T 0.67 
rs800165 0.028 0.005 T T 0.343 
rs10138240 0.029 0.005 G G 0.514 
Short Sleep   
rs7524118 -0.00576 0.001054 T C 0.291624 
rs2186122 -0.00567 0.000972 A T 0.438434 
rs12567114 0.006325 0.001077 G A 0.7246 
rs2820313 -0.00601 0.00101 A G 0.658888 
rs1380703 -0.00676 0.001005 A G 0.616469 
rs2863957 0.01019 0.001161 C A 0.781508 
rs2014830 0.005786 0.00105 C T 0.698128 
rs17005118 -0.00648 0.001087 G A 0.735064 
rs13107325 -0.01327 0.001828 C T 0.925472 
rs12518468 -0.00589 0.001021 T C 0.671544 
rs3776864 0.005724 0.001019 A C 0.66721 
rs4585442 -0.00635 0.001036 A G 0.688977 





 rs9367621 0.005445 0.00097 T A 0.43104 
rs9321171 0.005354 0.000966 C T 0.540122 
rs11763750 0.007212 0.001234 G A 0.814346 
rs1229762 -0.00724 0.001017 C T 0.335499 
rs60882754 0.011304 0.002001 A T 0.938985 
rs1607227 0.006369 0.001055 G T 0.704938 
rs7939345 0.006498 0.001182 T G 0.207569 
rs17388803 -0.00983 0.001587 A C 0.894352 
rs59779556 0.005491 0.000966 T G 0.553827 
rs205024 0.00551 0.000986 C T 0.616724 
rs12963463 0.007114 0.00106 C T 0.299425 
rs5757675 0.006455 0.001099 G T 0.259528 
Long Sleep   
rs10899255 -0.00562 0.001032 G A 0.855558 
rs149980149 -0.01192 0.002226 C G 0.971827 
rs5848 0.004465 0.00082 C T 0.721799 
rs62158160 -0.00501 0.00083 C T 0.742431 
rs72630583 -0.0047 0.000882 C T 0.783789 
rs73608603 -0.00598 0.001073 A G 0.867766 
rs75458655 -0.01673 0.002423 C T 0.977027 
rs8047395 0.003957 0.000728 G A 0.50028 
EA: effect allele; OA: other allele, EAF: effect allele frequency; GX: the per-allele effect on 




Figure 1. Flow chart of study selection.





Figure 2: Forest plot of stroke risk associated with <7 hours sleep (Favours A) compared to
7-8 hours sleep (Favours B) from 25 studies. Results are expressed as risk ratios and 95%
confidence intervals. Pooled analysis: p <0.001; heterogeneity test: I2 = 71.4, p <0.001. The
area of each block is proportional to the weight attributed to each study.




Figure 3: Forest plot of stroke risk associated with <5 hours sleep (Favours A) compared to
7-8 hours sleep (Favours B) from 13 studies. Results are expressed as risk ratios and 95%
confidence intervals. Pooled analysis: p <0.001; heterogeneity test: I2 = 58.4, p <0.001. The
area of each block is proportional to the weight attributed to each study.





Figure 4: Forest plot of stroke risk associated with 6 hours sleep (Favours A) compared to
7-8 hours sleep (Favours B) from 12 studies. Results are expressed as risk ratios and 95%
confidence intervals. Pooled analysis: p = 0.110; heterogeneity test: I2 = 52.6, p = 0.016.
The area of each block is proportional to the weight attributed to each study.





Figure 5: Forest plot of stroke risk associated with >8 hours sleep (Favours A) compared to
7-8 hours sleep (Favours B) from 16 studies. Results are expressed as risk ratios and 95%
confidence intervals. Pooled analysis: p <0.001; heterogeneity test: I2 = 53.6, p <0.001. The
area of each block is proportional to the weight attributed to each study.
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